ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 557

Translation and Cross-Cultural Adaptation of the ASAS Health Index and the environmental Item Set into 15 Languages

Uta Kiltz1, Désirée van der Heijde2, Annelies Boonen3, Wilson Bautista - Molano4, Ruben Burgos-Vargas5, Praveena Chiowchanwisawakit6, M Tuncay Duruoz7, Bassel El-Zorkany8, Inna Gaydukova9, Ivette Essers10, Pál Géher11, Laure Gossec12, Simeon Grazio13, Jieruo Gu14, Muhammad Asim Khan15, Tae.Jong Kim16, Walter P. Maksymowych17, Helena Marzo-Ortega18, Victoria Navarro-Compan19, Ignazio Olivieri20, Dimos Patrikos21, Fernando Pimentel-Santos22, Filip van Den Bosch23, Jane Zochling24 and Juergen Braun1, 1Rheumazentrum Ruhrgebiet, Herne, Germany, 2Dept of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 3Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Center, Maastricht, Netherlands, 4Spondyloarthritis Group. Rheumatology Division. Hospital Militar Central/Universidad de La Sabana. Bogotá. Colombia, Bogotá, Colombia, 5Rheumatology, Universidad Nacional Autónoma de México, Mexico, Mexico, 6The Offices at Central World,, Siriraj Hospital, Bangkok, Thailand, 7Dept of PM&R, Rheumatology Clinic, Marmara Univ Med Schl, Istanbul, Turkey, 8Cairo University, Cairo, Egypt, 9Hospital Therapy, Saratov State Medical University, Saratov, Russia, 10School for Public Health and Primary Care (CAPHRI), Maastricht University, Maastricht, Netherlands, 11Budai Irgalmasrendi Korhaz, Budapest, Hungary, 12Rheumatology, UPMC GRC08, Paris 06 University, Pitié Salpétrière Hospital, Paris, France, 13Clinical Hospital Center Sestre Milosrdnice, Zagreb, Croatia, 14Rheumatology, The Affiliated Third Hospital of Sun Yat-san University, Rheumatology, Guangzhou, China, 15Medicine/ Rheumatology, CASE at MetroHealth Med Center, Cleveland, OH, 16Chonnam Nat`l University Medical School&Hospital, Chonnam, South Korea, 17Medicine, University of Alberta, Edmonton, AB, Canada, 18University of Leeds and NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds, United Kingdom, 19University Hospital La Paz, Madrid, Spain, 20Rheumatology Department of Lucania, San Carlo Hospital of Potenza and Madonna delle Grazie Hospital of Matera, Potenza, Italy, 21138 MESOGEION AVE & KATECHAKI, 401 Military Hospital Of Athens, Athens, Greece, 22Rheumatology, Centro Hospitalar de Lisboa Ocidental, Hospital Egas Moniz, Lisboa, Portugal, 23Rheumatology, Department of Rheumatology Ghent University Hospital, Ghent, Belgium, 24Menzies Research Institute Tasmania, Hobart, Australia

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Health Assessment Questionnaire and spondylarthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Spondyloarthropathies and Psoriatic Arthritis - Clinical Aspects and Treatment I

Session Type: Abstract Submissions (ACR)

Background/Purpose: The ASAS Health Index (ASAS HI) is a unidimensional questionnaire measuring health and impairment in functioning in patients with spondyloarthritis (SpA). The ASAS HI is accompanied by a multidimensional item set aiming at measuring environmental factors (EF Item Set). These two disease-specific questionnaires are the first questionnaires which have been developed based on the International classification of functioning, disability and health (ICF). The ASAS HI contains 17 dichotomous items addressing categories of pain, emotional functions, sleep, sexual function, mobility, self care, and community life and the EF Item Set contains 9 dichotomous items addressing categories of support/relationships, attitudes and health services. The objective is to translate and adapt the ASAS HI and the EF Item Set cross-culturally into 15 languages with 17 versions and to field test the new versions in patients with axial SpA (axSpA).

Methods: Translation and cross-cultural adaptation was done in 20 countries according to published recommendations (forward-backward procedure) in 5 steps: translation, synthesis of translation, back translation, expert committee review and pre-testing in a field test. The field test was conducted in patients with axSpA to test its applicability in patients with all forms of SpA.

Results: The ASAS HI and EF Item Set was translated into Arabic, Chinese, Croatian, Dutch/Flemish, French, German, Greek, Hungarian, Italian, Korean, Portuguese, Russian, Spanish (Colombia, Mexico, Spain), Thai, and Turkish. 206 patients (approximately 10 patients/country, 59.7% male, mean (SD) age 42.4 (13.9) years, mean (SD) BASDAI 3.8 (2.3)) with axSpA underwent qualitative interviews during field testing in 23 countries (19 non-English speaking countries, 4 English-speaking countries). 65% of the patients were diagnosed with AS, 35% with non-radiographic axSpA and 33% of the total sample size suffered from peripheral involvement. Interviews showed the English questionnaire and the translations to be clear, relevant and comprehensive. All versions were accepted with minor modifications. The total sum of the ASAS HI (range 0-17, with a lower score indicating a better health status) was 7.1 ± 4.4 (mean ± SD). Completion times for ASAS HI and for EF Item Set were respectively, 2.6 ± 1.6 and 2.1 ± 1.5 (mean ± SD) minutes.

Conclusion: The ASAS HI and the EF Item Set were successfully translated into 15 languages with 17 versions. This study showed the ASAS HI items to be readily adaptable throughout countries, indicating the concepts covered may be meaningful in many cultures. In the other hand, more difficulties were experienced with the contextual factors indicating these concepts may be more culture-dependent. The field test suggested that the English and the non-English versions have high face and content validity. By investigating patients with axSpA with and without peripheral manifestations it could be shown that the ASAS HI and the EF Item Set are valid to be applied in patients with all forms of SpA. Further validation is underway to test the psychometric properties of this new disease-specific questionnaire.


Disclosure:

U. Kiltz,
None;

D. van der Heijde,
None;

A. Boonen,
None;

W. Bautista – Molano,
None;

R. Burgos-Vargas,
None;

P. Chiowchanwisawakit,
None;

M. T. Duruoz,
None;

B. El-Zorkany,
None;

I. Gaydukova,
None;

I. Essers,
None;

P. Géher,
None;

L. Gossec,
None;

S. Grazio,
None;

J. Gu,
None;

M. A. Khan,
None;

T. J. Kim,
None;

W. P. Maksymowych,
None;

H. Marzo-Ortega,

UCB Pharma,

5;

V. Navarro-Compan,
None;

I. Olivieri,
None;

D. Patrikos,
None;

F. Pimentel-Santos,
None;

F. van Den Bosch,
None;

J. Zochling,
None;

J. Braun,

Abbvie (Abbott), Amgen, BMS, Boehringer, Celgene, Celltrion, Centocor, Chugai, EBEWE Pharma, Medac, MSD (Schering-Plough), Mundipharma, Novartis, Pfizer (Wyeth), Roche, Sanofi-Aventis and UCB,

9,

Abbvie (Abbott), Amgen, BMS, Boehringer, Celgene, Celltrion, Centocor, Chugai, EBEWE Pharma, Medac, MSD (Schering-Plough), Mundipharma, Novartis, Pfizer (Wyeth), Roche, Sanofi-Aventis and UCB,

9,

Abbvie (Abbott), Amgen, BMS, Boehringer, Celgene, Celltrion, Centocor, Chugai, EBEWE Pharma, Medac, MSD (Schering-Plough), Mundipharma, Novartis, Pfizer (Wyeth), Roche, Sanofi-Aventis and UCB,

5,

Abbvie (Abbott), Amgen, BMS, Boehringer, Celgene, Celltrion, Centocor, Chugai, EBEWE Pharma, Medac, MSD (Schering-Plough), Mundipharma, Novartis, Pfizer (Wyeth), Roche, Sanofi-Aventis and UCB,

2.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/translation-and-cross-cultural-adaptation-of-the-asas-health-index-and-the-environmental-item-set-into-15-languages/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology